Original from: 360DX

Genetron Health said Friday that it has entered into an exclusive agreement with Jiangsu Fosun Pharmaceutical Sales, a subsidiary of Shanghai Fosun Pharmaceutical, to commercialize its minimal residual disease assay Seq-MRD.

Under the agreement, Genetron and Jiangsu Fosun will co-market and co-promote Seq-MRD in hematologic-focused hospitals and clinics across designated territories in China, which serve patients with lymphoid malignancies including acute lymphoblastic leukemia, multiple myeloma, and chronic lymphoid leukemia.

The partnership marks the launch of Genetron's first MRD product, which the firm said it has tested across thousands of samples of ALL, MM, and CLL in China.

Genetron highlighted Jiangsu's sizeable hematologic cancer-focused sales force and relationships with clinics, hospitals and distributors as an asset in driving clinical adoption.

"Seq-MRD offers significant advantages over conventional detection methods and has significant market potential in China. Our partnership's goal is to increase Seq-MRD's market penetration and turn it into a standardized NGS-based MRD test," said Wu Yifang, chairman and CEO of Fosun Pharma, in a statement. "We believe that our capabilities and network can maximize the product's commercialization potential."

Financial terms of the deal were not disclosed.